HIF-2α

Overview

HIF-2α (hypoxia-inducible factor 2 alpha) is a subunit of the hypoxia-inducible factor family of transcription factors that helps cells adapt to low-oxygen conditions. Like HIF-1α, it is regulated by oxygen availability and participates in the transcriptional control of genes involved in angiogenesis, metabolism, cell growth, and stress responses. In disease settings, HIF-2α is especially important in hypoxia-driven tumor biology, where it can support tumor progression and therapeutic resistance.

As a drug target, HIF-2α has attracted major interest in oncology, particularly in clear cell renal cell carcinoma (ccRCC), where VHL loss leads to aberrant HIF signaling. Recent studies have also examined HIF-2α in liver cancer and gastric cancer, and in the regulation of pathways linked to oxidative stress, glucose and lipid metabolism, and exosomal signaling. Its PAS-B domain contains a ligandable lipophilic pocket that has been exploited for small-molecule inhibition, making HIF-2α one of the best-characterized transcription factor targets in modern cancer pharmacology.

Focus of Latest Publications

Recent publications have continued to position HIF-2α as a central regulator of hypoxia-adaptive and tumor-promoting programs, while also refining how it can be therapeutically targeted.

One study described the discovery and characterization of Casdatifan, a new class of N-aryl-substituted tetrahydroquinolines designed to bind the HIF-2α PAS-B domain with high affinity. This work focused on structure-activity relationships and supports the idea that the HIF-2α lipophilic pocket can be exploited for selective inhibitor design. The study is consistent with the broader development of HIF-2α-directed therapies such as belzutifan, which has already established clinical relevance in kidney cancer.

Another publication examined how HIF-2α inhibitors are being used in clear cell renal cell carcinoma, including combination strategies involving cabozantinib, lenvatinib, and pembrolizumab. The report emphasized that HIF-2α inhibition remains clinically important in kidney cancer and that combination approaches are being explored to improve outcomes. In parallel, a genome-wide CRISPR interference (CRISPRi) screen identified a cytokine-enhancer circuit that drives HIF-2α activation in renal cancer, highlighting that resistance to HIF-2α inhibitors such as belzutifan may arise from upstream transcriptional regulation rather than only from changes in the protein target itself.

HIF-2α was also studied in the context of broader anti-hypoxia drug development. A paper on targeting conserved domains of hypoxia-inducible factors reported compounds that bind directly to conserved regions of HIF-1α and HIF-2α, disrupt dimerization with HIF-1β, and trigger proteasomal degradation. This suggests that HIF-2α can be inhibited not only through PAS-B pocket binding but also through strategies that interfere with transcription factor assembly and stability.

In liver cancer, HIF-2α was shown to drive RNF126 expression under hypoxia. RNF126 then ubiquitinates the peroxisomal membrane transporter ABCD3, triggering pexophagy and depletion of peroxisomes. This links HIF-2α to organelle remodeling and metabolic adaptation in hepatocellular carcinoma, and it connects HIF-2α signaling to oxidative stress and redifferentiation-related biology.

In gastric cancer, HIF-2α was reported to transcriptionally activate exosomal ITGβ5, promoting tumor progression. This work suggests that HIF-2α can influence intercellular communication through exosome-associated mechanisms, potentially affecting invasion, metastasis, or the tumor microenvironment. The study also reinforces the role of HIF-2α as a transcriptional regulator of cancer-associated programs beyond renal malignancy.

Finally, a study on clinically approved HIF-PHIs reported that these agents modulate redox metabolism, cell growth, and angiogenesis independently of HIF-1α/HIF-2α, while still stabilizing hypoxia-inducible factors in general. This provides useful context for HIF-2α biology by distinguishing direct HIF-2α targeting from upstream oxygen-sensing interventions.

Key Publications

Jul Clinically approved HIF-PHIs modulate redox metabolism, cell growth, and angiogenesis independent of HIF-1α/HIF-2α. (Redox biology, 2026, PMID 42150425): "These drugs stabilize hypoxia-inducible factors HIF-1α and HIF-2α"
Jun Discovery of Casdatifan, Part I: Design and Characterization of Tetrahydroquinoline Inhibitors of Hypoxia-Inducible Factor-2α. (Journal of medicinal chemistry, 2026, PMID 42053090): "Here, we report the design and structure-activity relationships of a novel class of N-aryl-substituted tetrahydroquinolines that bind the HIF-2α PAS-B domain with high affinity."
Jun RNF126 is a peroxisomal fate switch enabling redifferentiation therapy in hepatocellular carcinoma. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 42263131): "Under hypoxia, HIF-2α drives RNF126 expression, which in turn ubiquitinates the peroxisomal membrane transporter ABCD3, triggering selective peroxisome autophagy (pexophagy) and depletion of peroxisomes."
May Genome-wide CRISPR screen identifies a cytokine-enhancer circuit driving HIF-2α activation in renal cancer. (The Journal of clinical investigation, 2026, PMID 41874563): "Resistance to HIF-2α inhibitors such as belzutifan underscores the need to better understand how HIF-2α is transcriptionally regulated in clear cell renal cell carcinoma (ccRCC)."
May Hypoxia-Driven HIF-2α Transcriptionally Activates Exosomal ITGβ5 to Promote Gastric Cancer Progression. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42087351): "However, the regulatory relationship and functional significance between HIF-2α and ITGβ5 in GC remain poorly understood."
May Targeting conserved domains of hypoxia-inducible factors for cancer therapy. (The Journal of experimental medicine, 2026, PMID 41941275): "...which bind directly to highly conserved domains of HIF-1α and HIF-2α, disrupt dimerization with HIF-1β, and trigger proteasomal degradation, thereby inhibiting HIF-1/2 transcriptional activity."
May HIF-2α Inhibitor Combinations Knock Back Kidney Cancer in Two Trials. (Cancer discovery, 2026, PMID 41805886): "...the potential benefits of the HIF-2α inhibitor belzutifan for patients with clear cell renal cell carcinoma."